Medical Device Definition in Singapore: The Intended Use Principle

1. Key takeaways

Whether a product constitutes a medical device in Singapore is decided by its intended use, not by its physical form or technical principle. Whenever the uses declared by the product owner — the manufacturer or brand owner — through labels, instructions for use and promotional materials fall within the scope of diagnosing, preventing, monitoring, treating or alleviating human disease or injury, the product constitutes a medical device under the Health Products Act and becomes subject to registration or product notification obligations. This single principle drives everything that follows: the words you print on a label or publish on a website can move a product across the regulatory boundary, and a boundary product can be re-characterised by nothing more than a shift in its claims.

• Intended use, as declared by the product owner in labelling and promotional materials, is the decisive factor for device qualification.
• Software is expressly covered: SaMD is governed by GL-04 R4, GL-07 R2 and GN-37 R1, and claiming diagnostic or therapeutic functions triggers full registration.
• IVDs follow their own classification rules under GN-14 R3, with additional guidance for IVD analysers under GN-34 R2.
• The exclusion for lifestyle and wellness products is conditional and fragile; any therapeutic claim re-qualifies the product as a device.

2. Legal basis

The table below sets out the legal instruments and guidance documents that define what counts as a medical device in Singapore, from the parent Act and its interpretation provision through to the classification rules and the specialised guidance for software and in vitro diagnostic devices.

Together these instruments form the qualification framework. The Act supplies the statutory definition through its First Schedule and interpretation section, the Regulations operationalise the obligations that attach once a product qualifies, and the GN/GL guidance explains how HSA applies the definitions to software, IVDs, accessories and combination products. A robust qualification decision cites all three layers and records why each one was reached.

3. Expert insights

Insight 1: Software is expressly brought within the device scope, and this is the trap Chinese manufacturers fall into most easily. HSA maintains an independent and mature guidance system for software as a medical device: GL-04 R4 provides a full life cycle approach, GL-07 R2 (July 2025) specifically addresses the risk classification of clinical decision support software (SAMD-CDSS), and GN-37 R1 sets out the change management plan (CMP) for SaMD incorporating machine learning functions. In our projects we have seen too many clients assume that they are merely selling an app or a cloud platform, only to find that because the product claims diagnostic or therapeutic uses, they are required to go through full registration. The consequence of discovering this late is not merely a delayed launch: the entire dossier architecture, the clinical evidence package and the quality system evidence must be built for a regulated device rather than an unregulated service.

Insight 2: In vitro diagnostics (IVDs) are a separate branch with different classification rules. IVDs do not apply the GN-13 rules for general devices; they are governed by GN-14 R3. In addition, HSA maintains dedicated guidance for IVD analysers in GN-34 R2 (October 2025). If a company’s product line includes both reagents and instruments, each item must be assessed separately and grouping strategy (GN-12) must be considered. Treating an instrument and the reagent kits that run on it as a single registration unit without checking the grouping rules is a common planning error, because the classification logic for the analyser and for the assays it performs follows different guidance documents and can lead to different risk classes.

Insight 3: The exclusion as “not a medical device” is conditional. Purely lifestyle-oriented or health-promotion products (for example body-shaping devices, massagers, magnetic jewellery, and wellness telehealth applications without medical claims) are generally not regarded as medical devices. But note that this exclusion is fragile — once expressions such as “assists treatment” or “improves a particular disease” enter the promotional language, the intended use shifts and the product may be re-characterised. In our market access reviews we examine the product label, the instructions for use and the website claims together, because all three must be internally consistent. A product that is clean on the label but carries therapeutic language on its e-commerce listing has not solved the problem; it has only relocated it.

Insight 4: Accessories and combination products require separate assessment. An accessory intended to be used with a specific medical device to enable that device to achieve its intended use is typically itself qualified as a medical device. Combination products that incorporate medicinal substances also follow different registration fees and pathways in Singapore compared with pure devices (for Class D devices containing a registrable medicine, the Abridged route is S$10,600 and the Full route is S$75,600). The cost differential is enormous and must be identified at the project initiation stage, not when the dossier is being assembled.

4. Practical recommendations

• Write the intended use statement before discussing registration: we require clients to produce, at project initiation, an intended use text confirmed jointly by the marketing, R&D and regulatory functions; all subsequent labels, instructions for use and promotional materials are benchmarked against it.
• Perform the SaMD determination early for software product lines: do not leave the judgment until just before submission; the classification outcome under GL-07 R2 directly affects the registration pathway and timeline.
• Fix boundary determinations in writing: for products determined to be outside the device definition, retain an internal determination file citing the relevant provisions, ready for HSA queries or customs checks.
• Bring promotional language into compliance review: advertising in Singapore is regulated by Part V of the Health Products Act and GN-08; a re-characterisation caused by marketing language will cascade into registration obligations.

5. Verification checklist

• □ The intended use statement of the product has been confirmed in writing
• □ A determination on software as a medical device has been made (with reference to GL-04 R4 / GL-07 R2)
• □ A determination on IVD status has been made (with reference to GN-14 R3)
• □ Accessories and combination products (including drug-device combinations) have been identified
• □ The label, instructions for use and promotional language are consistent with one another
• □ Boundary products have a retained determination file with cited provisions

Regulatory information verified as of: 26 October 2026

Source level: Tier 1 (Health Products Act 2007), Tier 2 (GL-06 R2, GN-13 R2.1, GN-14 R3, GL-04 R4, GN-34 R2)

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Singapore. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with HSA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com